GlobeNewsWire
09 Oct 2026, 00:03 UTC · 14h ago
AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD
Impact · against what's priced in
Aardvark Therapeutics faces potential negative pressure as a legal deadline approaches for a class action lawsuit alleging safety issues with its lead drug ARD-101. The news reinforces claims that the company's clinical and commercial prospects were overstated.
- AARD−0.60
No priced-in read yet





